NMS·Healthcare·$933M·#207 / 520 in Healthcare
ABUS Arbutus Biopharma Corporation
52SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY0
STABILITY39
VALUATION71
GOVERNANCE84
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+128.2%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
5 months
9
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
1.0%
99
< 25% strong
Price / Sales
Market cap relative to trailing revenue
4.9x
71
< 3x strong
Rule of 40
Growth rate plus operating margin
-64
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
20.5%
86
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+3.1%
82
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ABUS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ABUS's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.